United Therapeutics Corporation (UTHR)
$546.38
$3.72
(0.69%)
As on 29-Jun-2026 14:41EDT
Market cap
$23,034 Mln
Revenue (TTM)
$3,170 Mln
P/E Ratio
20.1
P/B Ratio
3.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.2 %
-
ROCE
19.3 %
-
Industry P/E
--
-
EV/EBITDA
11.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$27
-
Face value
--
-
Shares outstanding
42,446,733
10 Years Aggregate
CFO
$5,562.10 Mln
EBITDA
$7,707.44 Mln
Net Profit
$5,310.71 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
United Therapeutics (UTHR)
| 12.1 | -2.8 | 4.5 | 92.2 | 36.5 | 25.3 | 18.3 |
|
BSE Sensex
| -9.4 | 1.1 | 4.3 | -8.7 | 6.3 | 7.8 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
United Therapeutics (UTHR)
| 38.1 | 59.8 | -20.9 | 28.7 | 42.4 | 72.3 | -19.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
United Therapeutics (UTHR)
|
546.4 | 23,034.1 | 3,169.8 | 1,287.4 | 51.3 | 20.6 | 20.1 | 3.9 |
| 293.9 | 38,901.6 | 4,286.9 | 577.2 | 20.3 | 88.2 | 73 | 36.2 | |
| 79.6 | 11,112.2 | 622.0 | -300.9 | -25.7 | -61.1 | -- | 18.2 | |
| 262.4 | 17,099.0 | 867.5 | 506.6 | -0.6 | -- | 30.3 | 30.9 | |
| 54.4 | 13,766.7 | 2,375.5 | 833.4 | 41.5 | 40.7 | 18.1 | 6.9 | |
| 192.1 | 28,000.8 | 16,632.0 | 1,385.0 | 14.1 | 22.3 | 20.9 | 4.5 | |
| 521.0 | 11,819.5 | 1,132.5 | -309.4 | -25.0 | -52.9 | -- | 21.7 | |
| 528.0 | 15,053.0 | 2,678.3 | 460.4 | 21.3 | 103.2 | 33.2 | 25.1 | |
| 629.6 | 66,352.6 | 14,919.6 | 4,423.4 | 34.9 | 14.2 | 15.5 | 2.1 | |
| 494.7 | 124,704.8 | 12,255.1 | 4,338.3 | 42.2 | 23.7 | 29.2 | 6.4 |
Shareholding Pattern
View DetailsAbout United Therapeutics (UTHR)
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an... inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland. Read more
-
Founder, Chairman & CEO
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
-
Founder, Chairman & CEO
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
-
Headquarters
Silver Spring, MD
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for United Therapeutics (UTHR)
What is the current share price of United Therapeutics Corporation (UTHR) Today?
The share price of United Therapeutics Corporation (UTHR) is $546.38 (NASDAQ) as of 29-Jun-2026 14:41 EDT. United Therapeutics Corporation (UTHR) has given a return of 36.51% in the last 3 years.
What is the current PB & PE ratio of United Therapeutics Corporation (UTHR)?
The P/E ratio of United Therapeutics Corporation (UTHR) is 20.09 times as on 26-Jun-2026.
The P/B ratio of United Therapeutics Corporation (UTHR) is 3.91 times as on 26-Jun-2026, a 20 discount to its peers’ median range of 4.86 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
17.49
|
3.29
|
|
2024
|
14.38
|
2.67
|
|
2023
|
11.12
|
1.83
|
|
2022
|
18.89
|
2.86
|
|
2021
|
21.71
|
2.61
|
What is the 52 Week High and Low of United Therapeutics Corporation (UTHR)?
The 52-week high and low of United Therapeutics Corporation (UTHR) are Rs 609.35 and Rs 272.12 as of 30-Jun-2026.
What is the market cap of United Therapeutics Corporation (UTHR)?
United Therapeutics Corporation (UTHR) has a market capitalisation of $ 23,034 Mln as on 26-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in United Therapeutics Corporation (UTHR)?
Before investing in United Therapeutics Corporation (UTHR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.